Cargando…

Co-administration with A1M does not influence apoptotic response of (177)Lu-octreotate in GOT1 neuroendocrine tumors

Recombinant α(1)-microglobulin (A1M) is a proposed radioprotector during (177)Lu-octreotate therapy of neuroendocrine tumors (NETs). To ensure a maintained therapeutic effect, we previously demonstrated that A1M does not affect the (177)Lu-octreotate induced decrease in GOT1 tumor volume. However, t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rassol, Nishte, Andersson, Charlotte, Pettersson, Daniella, Al-Awar, Amin, Shubbar, Emman, Kovács, Anikó, Åkerström, Bo, Gram, Magnus, Helou, Khalil, Forssell-Aronsson, Eva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115890/ https://www.ncbi.nlm.nih.gov/pubmed/37076494 http://dx.doi.org/10.1038/s41598-023-32091-9

Ejemplares similares

Hyperfractionated Treatment with (177)Lu-Octreotate Increases Tumor Response in Human Small-Intestine Neuroendocrine GOT1 Tumor Model
por: Elvborn, Mikael, et al.
Publicado: (2022)

Transcriptional effects of (177)Lu-octreotate therapy using a priming treatment schedule on GOT1 tumor in nude mice
por: Spetz, Johan, et al.
Publicado: (2019)

Neuroblastoma xenograft models demonstrate the therapeutic potential of (177)Lu-octreotate
por: Romiani, Arman, et al.
Publicado: (2021)

(177)Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition
por: Hofving, Tobias, et al.
Publicado: (2019)

Hedgehog inhibitor sonidegib potentiates (177)Lu-octreotate therapy of GOT1 human small intestine neuroendocrine tumors in nude mice
por: Spetz, Johan, et al.
Publicado: (2017)

Distinct microRNA Expression Profiles in Mouse Renal Cortical Tissue after (177)Lu-octreotate Administration
por: Schüler, Emil, et al.
Publicado: (2014)

Priming increases the anti-tumor effect and therapeutic window of (177)Lu-octreotate in nude mice bearing human small intestine neuroendocrine tumor GOT1
por: Dalmo, Johanna, et al.
Publicado: (2017)

Potential Biomarkers for Radiation-Induced Renal Toxicity following (177)Lu-Octreotate Administration in Mice
por: Schüler, Emil, et al.
Publicado: (2015)

Identification of Potential MR-Derived Biomarkers for Tumor Tissue Response to (177)Lu-Octreotate Therapy in an Animal Model of Small Intestine Neuroendocrine Tumor
por: Montelius, Mikael, et al.
Publicado: (2018)

Estimation of absorbed dose to the kidneys in patients after treatment with (177)Lu-octreotate: comparison between methods based on planar scintigraphy
por: Larsson, Maria, et al.
Publicado: (2012)

Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate
por: Bergsma, Hendrik, et al.
Publicado: (2016)

Evaluation of retinol binding protein 4 and carbamoylated haemoglobin as potential renal toxicity biomarkers in adult mice treated with (177)Lu-octreotate
por: Dalmo, Johanna, et al.
Publicado: (2014)

Binding of TS1, an anti-keratin 8 antibody, in small-cell lung cancer after (177)Lu-DOTA-Tyr(3)-octreotate treatment: a histological study in xenografted mice
por: Erlandsson, Ann, et al.
Publicado: (2011)

In Vivo Measurement and Characterization of a Novel Formulation of [(177)Lu]-DOTA-Octreotate
por: Bailey, Dale L, et al.
Publicado: (2016)

Accuracy and reproducibility of simplified QSPECT dosimetry for personalized (177)Lu-octreotate PRRT
por: Del Prete, Michela, et al.
Publicado: (2018)

Protection of Kidney Function with Human Antioxidation Protein α(1)-Microglobulin in a Mouse (177)Lu-DOTATATE Radiation Therapy Model
por: Kristiansson, Amanda, et al.
Publicado: (2019)

Effects of therapy with [(177)Lu-DOTA(0),Tyr(3)]octreotate on endocrine function
por: Teunissen, Jaap J. M., et al.
Publicado: (2009)

Potentiation of (177)Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor
por: Purohit, Nupur K., et al.
Publicado: (2018)

Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course
por: Bergsma, Hendrik, et al.
Publicado: (2015)

Evaluation of two intraoperative gamma detectors for assessment of (177)Lu activity concentration in vivo
por: Sandblom, Viktor, et al.
Publicado: (2017)

Report on short-term side effects of treatments with (177)Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours
por: van Essen, Martijn, et al.
Publicado: (2008)

Salvage peptide receptor radionuclide therapy with [(177)Lu-DOTA,Tyr(3)]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours
por: van der Zwan, W. A., et al.
Publicado: (2018)

Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of (177)Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells
por: Shah, Rashmi G., et al.
Publicado: (2021)

Cellular dosimetry of [(177)Lu]Lu-DOTA-[Tyr(3)]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity
por: Tamborino, Giulia, et al.
Publicado: (2020)

Salvage PRRT with (177)Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival
por: Rudisile, S., et al.
Publicado: (2019)

Phase I study of the (177)Lu-DOTA(0)-Tyr(3)-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung
por: Kim, Chul, et al.
Publicado: (2020)

Recombinant α(1)-Microglobulin (rA1M) Protects against Hematopoietic and Renal Toxicity, Alone and in Combination with Amino Acids, in a (177)Lu-DOTATATE Mouse Radiation Model
por: Alattar, Abdul Ghani, et al.
Publicado: (2023)

Bone marrow dosimetry in peptide receptor radionuclide therapy with [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: Forrer, Flavio, et al.
Publicado: (2009)

Long-term transcriptomic and proteomic effects in Sprague Dawley rat thyroid and plasma after internal low dose (131)I exposure
por: Larsson, Malin, et al.
Publicado: (2020)

Correction: Long-term transcriptomic and proteomic effects in Sprague Dawley rat thyroid and plasma after internal low dose 131I exposure
por: Larsson, Malin, et al.
Publicado: (2021)

Renal function affects absorbed dose to the kidneys and haematological toxicity during (177)Lu-DOTATATE treatment
por: Svensson, Johanna, et al.
Publicado: (2015)

High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer
por: Shubbar, Emman, et al.
Publicado: (2013)

Multimodal Somatostatin Receptor Theranostics Using [(64)Cu]Cu-/[(177)Lu]Lu-DOTA-(Tyr(3))octreotate and AN-238 in a Mouse Pheochromocytoma Model
por: Ullrich, Martin, et al.
Publicado: (2016)

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: de Keizer, Bart, et al.
Publicado: (2008)

Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [(177)Lu-[DOTA0, Tyr3]-octreotate
por: Santoro, Lore, et al.
Publicado: (2018)

177Lu-DOTA-0-Tyr3-octreotate infusion modeling for real-time detection and characterization of extravasation during PRRT
por: Mazzara, Christophe, et al.
Publicado: (2022)

Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA(0),Tyr(3)]-Octreotate and Lu-177-DKFZ-PSMA-617 therapy: investigation of a new hybrid image approach
por: Gosewisch, Astrid, et al.
Publicado: (2018)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

Pan-cancer analysis of genomic and transcriptomic data reveals the prognostic relevance of human proteasome genes in different cancer types
por: Larsson, Peter, et al.
Publicado: (2022)

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: Kwekkeboom, D. J., et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_mhrcg9467qb5fjt5ljq7rvack1